Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer

American Journal of Clinical Pathology
Beth Z ClarkRohit Bhargava

Abstract

We hypothesized that prognostic accuracy of the residual disease in breast and lymph nodes (RDBN) method, which is calculated using residual tumor size, nodal involvement, and tumor grade, may be improved by incorporating residual tumor cellularity. Cases included 614 patients who underwent neoadjuvant therapy for breast cancer. Tumor size was adjusted for residual cellularity of invasive carcinoma and used to calculate modified RDBN (mRDBN) and compared with unmodified gross tumor size (gRDBN). RDBN could be calculated in 428 cases. Relative risks of recurrence and death were significantly higher for RDBN-3 and RDBN-4 compared with RDBN-1. Kaplan-Meier analysis showed significant differences in disease-free survival and overall survival for estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (HER2)-negative and ER-positive/HER2-negative subgroups (P < .0001). Both mRDBN and gRDBN provide prognostic information, particularly in HER2-negative carcinoma; however, mRDBN showed better stratification of RDBN-3 and RDBN-4 patients.

References

Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherN V Dimitrov
Nov 1, 2002·Breast Cancer Research and Treatment·Hervé CuréPhilippe Chollet
Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·Keith N OgstonSteven D Heys
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Véronique DiérasPierre Pouillart
Aug 4, 2005·Journal of the National Cancer Institute·Lisa A CareyMark L Graham
Apr 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry D BearNorman Wolmark
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannGunter von Minckwitz
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chafika MazouniLajos Pusztai
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Nov 26, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Rohit BhargavaGretchen M Ahrendt
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A MittendorfKelly K Hunt
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Feb 19, 2013·Breast Cancer Research and Treatment·Janice DiazSusan Fineberg
May 2, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Florentia PeintingerW Fraser Symmans
Jul 25, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Elena ProvenzanoUNKNOWN Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collabo
Jun 15, 2016·American Journal of Clinical Pathology·Xiaoxian Bill LiRitu Aneja

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.